Replies to post #290984 on BOUNCE (BOING)

[ash111]

i think SPHS will be trading over NYMX 's PPS (3.46 currently) the near future.
NYMX Not only trading 6 times SPHS' s cap( on negative Cash flow) but also i see no Annual Report for NYMX since March 2015. last time the balance sheet has been very bad on negative Cash flow.
http://www.nymox.com/default.action?itemid=18

if something will go wrong here this will ended under .50,imo

while SPHS already reported positive P3 data and already funded to P2 Localized prostate cancer(huge mrkt,data will be released in Q1 2016),and also Analyst Doug Loe writes that "Our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial"

1. 11/10 pr: Positive phase 3 results.
http://ih.advfn.com/p.php?pid=nmona&article=69245847

2. 16,844,73 O/S, so market cap is less than $30m now.it's a joke market value if you compare it the other phase 3 bios and also to competitor (trading 6 times cap on a negative cash flow).

3. Zack is rated SPHS as a #1 buy.Average PT is over $6. the positive P3 data alone=$6,imo

4. SPHS already Funded to P2 Localized prostate cancer(huge mrkt,data will be released in Q1 2016).and per Analyst Doug Loe: "Our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial".

5. Last 10Q: "The Company expects that its cash, cash equivalents and securities available-for-sale as of September 30, 2015 will be sufficient to fund its operations through the end of April 2016"...

6. The balance sheet Solid.Total assets > Total liabilities.

7. Treatment has “blockbuster” potential – meaning annual sales of more than $1 billion:
3 separate analysis predicted annual sales between $700m to $3B

8. "Analyst Doug Loe writes that not only was the study a positive data point, “but particularly so when considering the multiple Phase 3 failures experienced by Sophiris’ BPH drug development peers in recent years, making the achievement of generating a positive Phase 3 efficacy signal in this difficult-to-treat medical market even more compelling.”
The key takeaway is that “we have heightened confidence in PRX-302’s approvability in the difficult-to-treat BPH market,” he added.
Mr. Loe also said the long-term efficacy in the PLUS-1 study from only a single intra-prostatic injection at enrollment is hugely positive for PRX-302’s medical and commercial prospects."

From the report: "Our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial.

Given the substantial size of the benign prostatic hyperplasia (BPH or enlarged prostate) market, we estimate peak sales over $700 million. We believe the company will achieve a favorable outcome in its 2nd Phase III trial, which we expect to have a reduced trial completion time. As such, we are buyers of Sophiris."

[ash111]

nice.1.80 res.broken.